The earnings call reflects a positive outlook for Xenon Pharmaceuticals, with significant progress in their epilepsy and neuropsychiatric programs, strong financial health, and promising early-stage pipeline developments. However, there are some uncertainties in the bipolar depression program and regulatory filing timeline. Overall, the positive advancements strongly outweigh the noted uncertainties.

Company Guidance -

Q3 2025

During Xenon Pharmaceuticals' Second Quarter 2025 Earnings Call, the company provided comprehensive guidance on several metrics and future plans. The company highlighted the completion of patient recruitment for their Phase III clinical trial, X-TOLE2, for azetukalner, targeting focal onset seizures, with top-line results expected in early 2026. They plan to submit an NDA for azetukalner upon positive results, aiming to launch their first commercial product. Additionally, Xenon has initiated trials in major depressive disorder and bipolar depression. Financially, they reported cash reserves of $624.8 million as of June 30, 2025, anticipating sufficient funds to support operations into 2027. The company also outlined their early-stage pipeline progress, including the initiation of Phase I studies for their Kv7 and Nav1.7 pain programs, and announced plans for a future R&D webinar to discuss these programs in detail. Xenon emphasized their strategic priorities, including expanding their product portfolio and advancing their ion channel programs, while preparing for potential commercialization.

Completion of Patient Recruitment for X-TOLE2

Xenon Pharmaceuticals has completed patient recruitment for their most advanced azetukalner Phase III clinical trial, X-TOLE2, which is a significant milestone and keeps them on track to report top-line results early in 2026.

Advancement in Epilepsy and Neuropsychiatric Programs

Initiated X-NOVA3 for major depressive disorder and X-CEED for bipolar depression, expanding azetukalner's potential beyond epilepsy to neuropsychiatric indications.

Strong Financial Position

Cash and cash equivalents and marketable securities totaled $624.8 million as of June 30, 2025, which is expected to fund operations into 2027.

Promising Early-Stage Pipeline

Initiated two Phase I studies within Kv7 and Nav1.7 programs for pain, showcasing significant momentum across the early-stage pipeline.

Strategic Hiring

Darren Cline joins as Chief Commercial Officer, bringing significant experience in epilepsy and successful product launches.

Xenon (XENE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XENE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-1.15 / -	-0.81	―	―	―
Aug 11, 2025	2025 (Q2)	-0.99 / -1.07	-0.75	-42.67% (-0.32)	―
May 12, 2025	2025 (Q1)	-0.90 / -0.83	-0.62	-33.87% (-0.21)	―
Feb 27, 2025	2024 (Q4)	-0.86 / -0.84	-0.64	-31.25% (-0.20)	―
Nov 12, 2024	2024 (Q3)	-0.82 / -0.81	-0.73	-10.96% (-0.08)	―
Aug 08, 2024	2024 (Q2)	-0.70 / -0.75	-0.72	-4.17% (-0.03)	―
May 09, 2024	2024 (Q1)	-0.66 / -0.62	-0.63	1.59% (+0.01)	―
Feb 29, 2024	2023 (Q4)	-0.76 / -0.64	-0.57	-12.28% (-0.07)	―
Nov 08, 2023	2023 (Q3)	-0.77 / -0.73	-0.57	-28.07% (-0.16)	―
Aug 09, 2023	2023 (Q2)	-0.70 / -0.72	-0.55	-30.91% (-0.17)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XENE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$34.11	$35.99	+5.51%
May 12, 2025	$35.85	$29.60	-17.43%
Feb 27, 2025	$38.31	$37.02	-3.37%
Nov 12, 2024	$43.39	$41.97	-3.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Xenon (XENE) report earnings?

Xenon (XENE) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Xenon (XENE) earnings time?

Xenon (XENE) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XENE EPS forecast?

XENE EPS forecast for the fiscal quarter 2025 (Q3) is -1.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing